Axovant Gene Therapies Ltd. (NASDAQ:AXGT) popped in on a low volume green day. Volume on 17-Jun-19 came in at 336945 contracts. The daily trading volume has averaged 663640 shares a day in past 5 days. The first sale was made at $5.21 but later the stock became weaker, and closed with a gain of 7.81%. It was last traded at $5.52 apiece.

Axovant Gene Therapies Ltd. (AXGT): Outperform Candidate With 552.17% Upside Potential

Axovant Gene Therapies Ltd. is maintained at an average outperform rating by 8 stock analysts, and there are at least 11.25% of shares outstanding that are currently legally short sold. The shares went down by -27.18% in value last month. Year-to-date it plunged -30.72%. Analysts are turning out to be more optimistic than before, with 5 of analysts who cover Axovant Gene Therapies Ltd. (NASDAQ:AXGT) advice adding it to buy candidate list. Wall Street experts also assign a $36 price target on Axovant Gene Therapies Ltd., pointing towards a 552.17% rally from current levels. The stock is trading for about -82.17% less than its 52-week high.

AXGT Adds 37.31% In A Week

This company shares (AXGT) so far managed to recover 44.88% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 13.01% while widening the period to a month, volatility was 11%. The share price has yet to cross its 20 days moving average, floating at a distance of -11.61% and sits -28.92% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 37.31% gains and is down by -52.94% compared with its 200-day moving average of $9.21. Also, Axovant Gene Therapies Ltd. (AXGT) needs to overturn a -81.55% decrease it experienced over the past twelve months.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Consensus Call At 1.4

As regular trading ended, Y-mAbs Therapeutics, Inc. (YMAB) stock brought in a -$1.53 drop to $20.78. The day started at a price of $22 but then traded as high as $22.5 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1.4. Y-mAbs Therapeutics, Inc. is given 3 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -32.97% from their peak of $31 and now has a $697.17 million market value of equity.

Y-mAbs Therapeutics, Inc. Could Grow 60.39% More

YMAB’s mean recommendation on Reuter’s scale presents no change from 1.4 thirty days ago to 1.4 now, which indicates a buy consensus from the analyst community. They see Y-mAbs Therapeutics, Inc. (YMAB) price hitting a mean target of $33.33 a share, meaning the stock still has potential that could lift the price another 60.39% . Also, the recent close suggests the stock is underpriced by 92.49% compared to the most bullish target.

Y-mAbs Therapeutics, Inc. (YMAB) Returns 2.16% This Year

The company had seen its current volume reaching at 389604 shares in the last trade. That compares with the recent volume average of 322080. At the close of regular trading, its last week’s stock price volatility was 6.26% which for the month reaches 7.26%. Y-mAbs Therapeutics, Inc. dipped to as low as $20.29 throughout the day and has returned 2.16% in this year. At one point in the past year, the shares traded as low as $15.17 but has recovered 36.98% since then. [T4]